IO Biotech (IO Biotech) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Change In Inventory?

IO Biotech's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means IO Biotech's inventory stayed the same from Dec. 2023 to Mar. 2024 .

IO Biotech's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means IO Biotech's inventory stayed the same from Dec. 2022 to Dec. 2023 .

IO Biotech's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IO Biotech Change In Inventory Historical Data

The historical data trend for IO Biotech's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Change In Inventory Chart

IO Biotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

IO Biotech Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial												-	-	-	-	-

IO Biotech Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

IO Biotech (NAS:IOBT) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

IO Biotech's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

IO Biotech's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

IO Biotech's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

IO Biotech Change In Inventory Related Terms

Thank you for viewing the detailed overview of IO Biotech's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

IO Biotech (IO Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200

Website

https://www.iobiotech.com

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Executives

Brian Burkavage	officer: Chief Accounting Officer	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma	10 percent owner	24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith	officer: General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad	officer: Chief Medical Officer	1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan	officer: Chief Financial Officer	38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier	director	1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson	director	1209 ORANGE STREET, WILMINGTON DE 19801